Astellas Pharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2830 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

Is It Too Late To Consider Astellas Pharma (TSE:4503) After An 83% One-Year Rally? - Feb 12th, 2026 12:09 am
India's Zydus Life agrees $120 million settlement with Astellas over bladder drug - Feb 11th, 2026 9:22 pm
PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight - Feb 10th, 2026 3:31 pm
India's Lupin settles US patent dispute with Astellas Pharma for $90 million - Feb 9th, 2026 10:32 pm
Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? - Feb 5th, 2026 6:48 am
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Jan 22nd, 2026 4:15 am
Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump? - Jan 15th, 2026 10:09 pm
Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Jan 15th, 2026 2:20 pm
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses - Jan 8th, 2026 8:30 am
Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment - Jan 8th, 2026 7:13 am
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 4:30 pm
How Attractive Is Astellas Pharma After a 44.1% Surge and Mixed Valuation Signals? - Dec 22nd, 2025 3:07 pm
Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503) - Dec 22nd, 2025 4:07 am
Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results - Dec 21st, 2025 6:09 pm
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Dec 17th, 2025 4:45 am
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - Dec 11th, 2025 5:30 am
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - Dec 10th, 2025 4:30 pm
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - Dec 5th, 2025 6:00 am
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Nov 25th, 2025 1:11 am
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally - Nov 22nd, 2025 5:12 am